New combo therapy aims to boost lymphoma remission in patients with key mutations
NCT ID NCT06846463
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding the oral drug zanubrutinib to standard chemotherapy (R-CHOP) can improve outcomes for people with diffuse large B-cell lymphoma (DLBCL) who have certain genetic mutations (MYD88, CD79B, NOTCH1) or a specific marker (CD5+). About 21 adults will receive the combination treatment. The main goal is to see how many achieve complete remission, with follow-up to track how long the benefit lasts.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Virginia Commonwealth University
RECRUITINGRichmond, Virginia, 23298, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Can an immune booster outsmart brain lymphoma?
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can donor immune cells be engineered to fight blood cancer?
- Can a simple blood test spot lymphoma earlier?
- Can a Four-Pronged attack beat brain lymphoma?